Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan

BACKGROUND: In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival versus placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy. After t...

Descripción completa

Detalles Bibliográficos
Autores principales: Asada, Noboru, Ando, Jun, Takada, Satoru, Yoshida, Chikashi, Usuki, Kensuke, Shinagawa, Atsushi, Ishizawa, Kenichi, Miyamoto, Toshihiro, Iida, Hiroatsu, Dobashi, Nobuaki, Okubo, Sumiko, Honda, Hideyuki, Soshin, Tomomi, Nishimura, Yasuko, Tsutsui, Atsuko, Mukai, Harumi, Yamamoto, Kazuhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311156/
https://www.ncbi.nlm.nih.gov/pubmed/37017320
http://dx.doi.org/10.1093/jjco/hyad027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311156/
https://www.ncbi.nlm.nih.gov/pubmed/37017320
http://dx.doi.org/10.1093/jjco/hyad027

Ejemplares similares